Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa
Name:
Sinanovic E - 2015 - Impact of ...
Size:
121.4Kb
Format:
PDF
Description:
Main article
Abstract
The cost of multidrug-resistant tuberculosis (MDR-TB) treatment is a major barrier to treatment scale-up in South Africa.PubMed ID
25574915Language
enISSN
1815-7920ae974a485f413a2113503eed53cd6c53
10.5588/ijtld.14.0421
Scopus Count
Collections
Related articles
- Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
- Authors: Schnippel K, Rosen S, Shearer K, Martinson N, Long L, Sanne I, Variava E
- Issue date: 2013 Jan
- Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
- Authors: Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E
- Issue date: 2018 Feb
- Cost per patient of treatment for rifampicin-resistant tuberculosis in a community-based programme in Khayelitsha, South Africa.
- Authors: Cox H, Ramma L, Wilkinson L, Azevedo V, Sinanovic E
- Issue date: 2015 Oct
- Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
- Authors: Bada FO, Blok N, Okpokoro E, Dutt S, Akolo C, Dakum P, Abimiku A
- Issue date: 2020
- Cost effectiveness of decentralised care model for managing MDR-TB in India.
- Authors: John D, Chatterjee P, Murthy S, Bhat R, Musa BM
- Issue date: 2018 Jul